Organigram (OGI.TO) stock price, revenue, and financials

Organigram market cap is C$478.5 m, and annual revenue was C$13.58 m in FY 2018

C$478.5 M

OGI.TO Mkt cap, 20-May-2022

C$31.8 M

Organigram Revenue Q2, 2022
Organigram Gross profit (Q2, 2022)6.9 M
Organigram Net income (Q2, 2022)-4 M
Organigram EBITDA (Q2, 2022)-8.2 M
Organigram EBIT (Q2, 2022)-15 M
Organigram Cash, 28-Feb-202282.3 M
Organigram EV404.1 M
Get notified regarding key financial metrics and revenue changes at OrganigramLearn more
Banner background

Organigram Revenue Breakdown

Embed Graph

Organigram revenue breakdown by business segment: 100.0% from PHARMACEUTICAL DIVERSIFIED

Organigram Income Statement

Annual

CADFY, 2018

Revenue

13.6m

Cost of goods sold

(3.5m)

Gross profit

56.1m

Operating expense total

(16.6m)

Depreciation and amortization

(3.5m)

EBITDA

39.5m

EBIT

34.8m

Interest expense

(10.1m)

Pre tax profit

26.2m

Income tax expense

(5.7m)

Net Income

20.5m

Quarterly

CADQ2, 2022

Revenue

31.8m

Cost of goods sold

(25.0m)

Gross profit

6.9m

R&D expense

(1.2m)

Operating expense total

(14.6m)

Depreciation and amortization

(3.4m)

EBITDA

(8.2m)

EBIT

(15.0m)

Interest expense

(90.0k)

Pre tax profit

(4.1m)

Income tax expense

97.0k

Net Income

(4.0m)

Organigram Balance Sheet

Annual

CADFY, 2018

Cash

55.1m

Accounts Receivable

793.0k

Prepaid Expenses

5.9m

Inventories

45.0m

Current Assets

203.2m

PP&E

98.6m

Total Assets

302.6m

Accounts Payable

10.8m

Short-term debt

421.0k

Current Liabilities

11.3m

Long-term debt

98.7m

Non-Current Liabilities

106.7m

Total Debt

99.2m

Total Liabilities

118.0m

Common Stock

157.8m

Retained Earnings

759.0k

Total Equity

184.6m

Quarterly

CADQ2, 2022

Cash

82.3m

Accounts Receivable

23.0m

Prepaid Expenses

6.3m

Inventories

42.9m

Current Assets

236.6m

PP&E

233.6m

Goodwill

42.0m

Total Assets

585.1m

Accounts Payable

25.6m

Short-term debt

5.0m

Current Liabilities

47.0m

Long-term debt

2.9m

Non-Current Liabilities

24.8m

Total Debt

7.8m

Total Liabilities

71.7m

Common Stock

769.4m

Retained Earnings

(281.0m)

Total Equity

513.4m

Organigram Cash Flow

Annual

CADFY, 2018

Net Income

22.1m

Depreciation and Amortization

3.5m

Accounts Receivable

337.0k

Inventories

(42.3m)

Accounts Payable

4.0m

Cash From Operating Activities

(12.7m)

Cash From Investing Activities

(98.0m)

Long-term Borrowings

107.6m

Cash From Financing Activities

163.9m

Net Change in Cash

53.1m

Quarterly

CADQ2, 2022

Net Income

(5.4m)

Depreciation and Amortization

12.1m

Accounts Receivable

(1.1m)

Inventories

(3.5m)

Accounts Payable

(864.0k)

Cash From Operating Activities

(10.1m)

Cash From Investing Activities

31.3m

Long-term Borrowings

(42.0k)

Cash From Financing Activities

5.8m

Net Change in Cash

26.9m

Organigram Ratios

CADFY, 2018

Revenue/Employee

38.2k

Organigram Operating Metrics

Organigram's Patients was reported to be 18.1 k in Q1, 2020.
Q1, 2017Q2, 2017Q3, 2017Q4, 2017Q1, 2018Q2, 2018Q3, 2018Q4, 2018Q1, 2019Q2, 2019Q3, 2019Q4, 2019Q1, 2020

Average Selling Price per Gram (Dried Cannabis)

C$5.4C$5.36C$5.62C$4.57

Brands

555443

Cannabis Harvested, kilograms

8.32 k6.05 k7.43 k12.76 k

Cannabis Sold, kilogram and kilogram equivalents

4.99 k4.62 k2.9 k5.5 k

Patients

4 k4.04 k5.51 k7.4 k10.73 k12.96 k15.32 k15.73 k13.51 k14.88 k17 k17.2 k18.13 k